BDSX
BIODESIX INC
$15.06
+1.76%
$156.0M
No data for this timeframe.
Vol
Market Cap$156.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders18 funds
Inst. Value$10.8M
Inst. Activity2 buys / 0 sells
Insider Activity0B / 10S
Insider Net $-$100.2K
SEC Reports3
Press Releases1
Recent Activity
Jun 1, 2026
SEC
Biodesix's S-3 shelf registration (File No. 333-296122) became effective on May 29, 2026, covering the resale of up to 3
EFFECT — Impact 4/10
May 21, 2026
other
Biodesix to Participate in Upcoming Investor Conferences
<p>LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading di
May 4, 2026
SEC
Biodesix reported Q1 2026 revenue of $25.6M (+42% YoY) and EPS of -$0.49, beating consensus estimates of $23.2M and -$1.
PRESS-RELEASE — Impact 8/10
Apr 20, 2026
SEC
Biodesix announced it will release Q1 2026 financial results on May 4, 2026, after market close, followed by a conferenc
PRESS-RELEASE — Impact 3/10
Mar 31, 2026
Insider
PATIENCE JOHN acquired via exercise 1,361 shares
Director
Feb 23, 2026
Insider
Pestano Gary Anthony sold 556 shares
Chief Development Officer @ $12.78 ($7.1K)
Feb 23, 2026
Insider
O'Kane Kieran sold 535 shares
Chief Commercial Officer @ $12.78 ($6.8K)
Inst.
Trexquant Investment LP — DOUBLED
69,601 shares ($1.0M)
Price Targets
$30.50
+102.5% upside
Strong Buy
Current $15.06
Low $22.00
Median $30.00
High $40.00
4 analysts
$22.00
$40.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Feb 27, 2026 | William Blair | UPGRADE | Market Perform → Outperform |
| Feb 17, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.92 ▼ -7.0% | $-1.03 — $-0.85 | 42% YoY | 5 |
| Next Q | $-0.81 ▼ -9.2% | $-0.86 — $-0.76 | 30% YoY | 5 |
| Current FY | $-3.02 ▲ +1.8% | $-3.18 — $-2.92 | 35% YoY | 5 |
| Next FY | $-1.82 ▲ +6.4% | $-2.50 — $-1.14 | 40% YoY | 5 |
Latest Reports
NEUTRAL
EFFECT
4/10
Biodesix's S-3 shelf registration (File No. 333-296122) became effective on May 29, 2026, covering the resale of up to 3
Jun 1, 2026
BULLISH
PRESS-RELEASE
8/10
Biodesix reported Q1 2026 revenue of $25.6M (+42% YoY) and EPS of -$0.49, beating consensus estimates of $23.2M and -$1.
May 4, 2026
BULLISH
Press
7/10
Biodesix announced the publication of a large clinical validation study for its Nodify CDT® test, demonstrating high spe
Mar 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.7M | — |
| MARSHALL WACE, LLP | $2.1M | — |
| Trexquant Investment LP | $1.0M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $655.9K | — |
| SEI INVESTMENTS CO | $623.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | PATIENCE JOHN | M | $0.00 |
| Feb 23, 2026 | Pestano Gary | SELL | $7.1K |
| Feb 23, 2026 | O'Kane Kieran | SELL | $6.8K |
| Feb 23, 2026 | Cowie Robin | SELL | $6.8K |
| Feb 23, 2026 | Vazquez Chris | SELL | $2.7K |
18 institutional holders with $10.8M total value (756,902 shares) as of 2026-Q1. Top holders: VANGUARD, MARSHALL, Trexquant. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 255,161 | $3.7M | 34.4% | — |
| 2 | MARSHALL WACE, LLP | 141,636 | $2.1M | 19.1% | — |
| 3 | Trexquant Investment LP | 69,601 | $1.0M | 9.4% | DOUBLED +152.7% |
| 4 | TWO SIGMA INVESTMENTS, LP | 45,231 | $655.9K | 6.1% | — |
| 5 | SEI INVESTMENTS CO | 43,024 | $623.8K | 5.8% | — |
| 6 | MORGAN STANLEY | 32,392 | $469.7K | 4.4% | DOUBLED +53001.6% |
| 7 | VANGUARD FIDUCIARY TRUST CO | 28,660 | $415.6K | 3.9% | — |
| 8 | BLAIR WILLIAM & CO/IL | 27,583 | $400.0K | 3.7% | — |
| 9 | BlackRock, Inc. | 24,466 | $354.8K | 3.3% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 23,090 | $334.8K | 3.1% | — |
| 11 | STATE STREET CORP | 17,802 | $258.1K | 2.4% | — |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 14,800 | $214.6K | 2.0% | — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 11,948 | $173.2K | 1.6% | — |
| 14 | Allworth Financial LP | 4,965 | $72.0K | 0.7% | — |
| 15 | Vanguard Global Advisers, LLC | 1,054 | $15.3K | 0.1% | — |
| 16 | GROUP ONE TRADING LLC | 100 | $1.4K | 0.0% | — |
| 17 | HRT FINANCIAL LP | 15,388 | $223.00 | 0.0% | — |
| 18 | FMR LLC | 1 | $15.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Trexquant Investment LP | DOUBLED | 27,542 | 69,601 | +152.7% | $1.0M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 61 | 32,392 | +53001.6% | $469.7K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 30 | 143 | +376.7% | $972.00 | 2025-Q4 |
6 unique insiders with 26 transactions. Net insider value: -$100.2K ($0.00 bought, $100.2K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | PATIENCE JOHN | Director | EXERCISE | 1,361 | — | — |
| Feb 23, 2026 | Pestano Gary Anthony | Chief Development Officer | SELL | 556 | $12.78 | $7.1K |
| Feb 23, 2026 | O'Kane Kieran | Chief Commercial Officer | SELL | 535 | $12.78 | $6.8K |
| Feb 23, 2026 | Cowie Robin Harper | CFO, Sec'y & Treasurer | SELL | 535 | $12.78 | $6.8K |
| Feb 23, 2026 | Vazquez Chris | Chief Accounting Officer | SELL | 211 | $12.78 | $2.7K |
| Feb 23, 2026 | Hutton Scott | President & CEO | SELL | 1,490 | $12.78 | $19.0K |
| Feb 20, 2026 | Pestano Gary Anthony | Chief Development Officer | EXERCISE | 1,528 | — | — |
| Feb 20, 2026 | O'Kane Kieran | Chief Commercial Officer | EXERCISE | 1,469 | — | — |
| Feb 20, 2026 | Cowie Robin Harper | CFO, Sec'y & Treasurer | EXERCISE | 1,469 | — | — |
| Feb 20, 2026 | Vazquez Chris | Chief Accounting Officer | EXERCISE | 563 | — | — |
| Feb 20, 2026 | Hutton Scott | President & CEO | EXERCISE | 4,844 | — | — |
| Feb 10, 2026 | Pestano Gary Anthony | Chief Development Officer | SELL | 540 | $10.08 | $5.4K |
| Feb 10, 2026 | Vazquez Chris | Chief Accounting Officer | SELL | 101 | $10.08 | $1.0K |
| Feb 10, 2026 | O'Kane Kieran | Chief Commercial Officer | SELL | 584 | $10.08 | $5.9K |
| Feb 10, 2026 | Cowie Robin Harper | CFO, Sec'y & Treasurer | SELL | 941 | $10.08 | $9.5K |
| Feb 10, 2026 | Hutton Scott | President & CEO | SELL | 3,559 | $10.08 | $35.9K |
| Feb 9, 2026 | Pestano Gary Anthony | Chief Development Officer | EXERCISE | 1,481 | — | — |
| Feb 9, 2026 | Pestano Gary Anthony | Chief Development Officer | EXERCISE | 68 | — | — |
| Feb 9, 2026 | Vazquez Chris | Chief Accounting Officer | EXERCISE | 263 | — | — |
| Feb 9, 2026 | Vazquez Chris | Chief Accounting Officer | EXERCISE | 28 | — | — |
| Feb 9, 2026 | O'Kane Kieran | Chief Commercial Officer | EXERCISE | 1,600 | — | — |
| Feb 9, 2026 | O'Kane Kieran | Chief Commercial Officer | EXERCISE | 73 | — | — |
| Feb 9, 2026 | Cowie Robin Harper | CFO, Sec'y & Treasurer | EXERCISE | 2,584 | — | — |
| Feb 9, 2026 | Cowie Robin Harper | CFO, Sec'y & Treasurer | EXERCISE | 157 | — | — |
| Feb 9, 2026 | Hutton Scott | President & CEO | EXERCISE | 9,998 | — | — |
| Feb 9, 2026 | Hutton Scott | President & CEO | EXERCISE | 610 | — | — |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
NEUTRAL
EFFECT
4/10
Biodesix's S-3 shelf registration (File No. 333-296122) became effective on May 29, 2026, covering t
Jun 1, 2026
BULLISH
PRESS-RELEASE
8/10
Biodesix reported Q1 2026 revenue of $25.6M (+42% YoY) and EPS of -$0.49, beating consensus estimate
May 4, 2026
NEUTRAL
PRESS-RELEASE
3/10
Biodesix announced it will release Q1 2026 financial results on May 4, 2026, after market close, fol
Apr 20, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$30.50 mean target
+102.5% upside
Strong Buy (3.00)
$22.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $15.06 |
| Target Low | $22.00 |
| Target Mean | $30.50 |
| Target Median | $30.00 |
| Target High | $40.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.92 | $-1.03 | $-0.85 | 42.4% | -7.0% | 1↑ 2↓ | $0.0B | 29.7% | 5 |
| Next Q 2026-09-30 |
$-0.81 | $-0.86 | $-0.76 | 30.3% | -9.2% | 0↑ 3↓ | $0.0B | 27.1% | 5 |
| Current FY 2026-12-31 |
$-3.02 | $-3.18 | $-2.92 | 35.3% | +1.8% | 1↑ 2↓ | $0.1B | 25.4% | 5 |
| Next FY 2027-12-31 |
$-1.82 | $-2.50 | $-1.14 | 39.7% | +6.4% | 1↑ 1↓ | $0.1B | 19.6% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.922 | |
| 7d ago | $-0.848 | -0.074 |
| 30d ago | $-0.862 | -0.060 |
| 60d ago | $-0.862 | -0.060 |
| 90d ago | $-0.653 | -0.269 |
2 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | William Blair | UPGRADE | Market Perform | Outperform |
| Feb 17, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
other
Biodesix to Participate in Upcoming Investor Conferences
<p>LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that
May 11, 2026
other
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals <pre>Includes real-world clinical data from Biode
May 4, 2026
earnings
Biodesix Announces First Quarter 2026 Results and Highlights
<p align="center"><em>Delivered $25.6 million in revenue representing 42% growth in Q1 2026;</em></p>
May 4, 2026
earnings_calendar
BDSX Q1 2026 Earnings Scheduled — 2026-05-04
Apr 20, 2026
earnings
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
<p>LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=XE2Kp-csvuw98G1xYgJXJMz0OsxuyU_MzrAXCTa
Apr 9, 2026
routine
Biodesix Recognized as a Top Workplace for Third Consecutive Year
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture <pre>Employee-Driven, Prestigious National Rec
Apr 6, 2026
other
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing <
Mar 20, 2026
fda
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient
Feb 26, 2026
earnings_calendar
BDSX Q4 2025 Earnings After Market Close — 2026-02-26